{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-058031","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.504583+00:00","generated_at":"2026-06-05T04:42:38.202950+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"low","headline":"Annexon holds virtual R&D Day focusing on Guillain-Barré Syndrome program","bullets":["Presentation highlighted serious unmet need in Guillain-Barré Syndrome and Annexon's novel therapeutic approach.","Webcast archive available on investor page for 30 days; CEO Douglas Love presented.","No financial results, guidance, or clinical data disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-058031","json":"https://secwatch.observer/filing/0001193125-24-058031.json","markdown":"https://secwatch.observer/filing/0001193125-24-058031.md","text":"https://secwatch.observer/filing/0001193125-24-058031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524058031/0001193125-24-058031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524058031/d790221d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:42:38.202950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}